Janus Henderson Group
CLDX icon

Janus Henderson Group’s Celldex Therapeutics CLDX Stock Holding History

Janus Henderson Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$814K Hold
25,642
– – ﹤0.01% 1778
2025
Q4 		$697K Hold
25,642
– – ﹤0.01% 1872
2025
Q3 		$663K Hold
25,642
– – ﹤0.01% 1873
2025
Q2 		$522K Hold
25,642
– – ﹤0.01% 1930
2025
Q1 		$511K Hold
25,642
– – ﹤0.01% 1952
2024
Q4 		$647K Hold
25,642
– – ﹤0.01% 1907
2024
Q3 		$871K Hold
25,642
– – ﹤0.01% 1743
2024
Q2 		$950K Sell
25,642
-280
-1% -$10.6K ﹤0.01% 1648
2024
Q1 		$1.09M Buy
25,922
+39
+0.2% +$1.6K ﹤0.01% 1600
2023
Q4 		$1.03M Buy
25,883
+8,863
+52% +$261K ﹤0.01% 1601
2023
Q3 		$468K Hold
17,020
– – ﹤0.01% 1952
2023
Q2 		$577K Sell
17,020
-25
-0.1% -$843 ﹤0.01% 1899
2023
Q1 		$614K Buy
17,045
+8,961
+111% +$387K ﹤0.01% 1901
2022
Q4 		$360K Buy
+8,084
New +$289K ﹤0.01% 1885
2022
Q3 		– Sell
-8,062
Closed -$217K – 2248
2022
Q2 		$217K Sell
8,062
-19
-0.2% -$552 ﹤0.01% 2259
2022
Q1 		$275K Buy
8,081
+2
+0% +$64 ﹤0.01% 2276
2021
Q4 		$312K Buy
8,079
+4,072
+102% +$177K ﹤0.01% 2179
2021
Q3 		$216K Buy
+4,007
New +$188K ﹤0.01% 2041

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Janus Henderson Group's CLDX Position: Q1 2026 in Review

Janus Henderson Group held its Celldex Therapeutics (CLDX) position steady in Q1 2026 at 25,642 shares worth $814K. The position accounts for ﹤0.01% of the portfolio, ranked #1778.

Janus Henderson Group first reported a position in CLDX in Q3 2021 and has held it in 18 quarters since. The position peaked at $1.09M in Q1 2024. 228 funds tracked by Wall St. Rank hold CLDX as of Q1 2026.

  • Janus Henderson Group held 25,642 shares of Celldex Therapeutics worth $814K as of Q1 2026.
  • Janus Henderson Group left its Celldex Therapeutics share count unchanged in Q1 2026.
  • Celldex Therapeutics made up ﹤0.01% of Janus Henderson Group's portfolio in Q1 2026, its #1778 holding.
  • Janus Henderson Group first reported a position in Celldex Therapeutics in Q3 2021 and has held it in 18 quarters since.
  • Janus Henderson Group's Celldex Therapeutics position peaked at $1.09M in Q1 2024.
  • 228 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2026.

Based on Janus Henderson Group's 13F filing for Q1 2026, filed 15 May 2026.